Adventrx Pharmaceuticals, Inc. (ANX)

ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The company was founded in 1995 is based in San Diego, California.

For the nine months ended 30 September 2006, Adventrx Pharmaceuticals, Inc.'s revenues totaled $710K, up from $261K. Net loss increased 1% to $22.9M. Revenues reflect higher interest income. Higher loss reflects increased research & development expenses, higher general & administrative expenses, increased depreciation & amortization charge and the presence of $10.4M In-process research and development expense.